# Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

> **NCT03152903** · PHASE2,PHASE3 · COMPLETED · sponsor: **Serum Institute of India Pvt. Ltd.** · enrollment: 2000 (actual)

## Conditions studied

- Prevention of TB Recurrence

## Interventions

- **BIOLOGICAL:** VPM1002 (Recombinant BCG Vaccine)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03152903
- **Lead sponsor:** Serum Institute of India Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2023-12-29
- **Final completion:** 2023-12-29
- **Target enrollment:** 2000 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03152903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03152903, "Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03152903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*